18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review, Cancer, vol.118, issue.8, pp.1971-1981, 2011. ,
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, The Lancet Oncology, vol.18, issue.4, pp.e206-e217, 2017. ,
Imaging in multiple myeloma: How? When?, Blood, vol.133, issue.7, pp.644-651, 2019. ,
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989?5995., Blood, vol.120, issue.11, pp.2349-2349, 2012. ,
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, issue.10, pp.2068-2076, 2009. ,
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study, Journal of Clinical Oncology, vol.35, issue.25, pp.2911-2918, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01726512
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3, Blood, vol.121, issue.10, pp.1819-1823, 2013. ,
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma, Clinical Cancer Research, vol.21, issue.19, pp.4384-4390, 2015. ,
International Myeloma Working Group Minimal Residual Disease Criteria, Lancet Oncol, vol.17, pp.328-346, 2020. ,
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nature Communications, vol.8, issue.1, p.268, 2017. ,
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma, Blood, vol.132, issue.1, pp.59-66, 2018. ,
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma, New England Journal of Medicine, vol.376, issue.14, pp.1311-1320, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01557406
Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Multiple Myeloma., Case Medical Research, vol.7, pp.456-468, 2020. ,
Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial, Blood, vol.128, issue.22, pp.992-992, 2016. ,
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe), European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.5, pp.712-719, 2017. ,
FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0, Eur J Nucl Med Mol Imaging, vol.42, pp.328-354, 2015. ,
The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: Focus on the Deauville criteria, Haematologica, vol.99, pp.84-85, 2014. ,
Report on the first international workshop on interim-PET-scan in lymphoma, Leuk Lymphoma, vol.50, pp.1257-1260, 2009. ,
International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-1473, 2006. ,
Maximally selected rank statistics, Biometrics, vol.48, pp.73-85, 1992. ,
Survival analysis in hematologic malignancies: Recommendations for clinicians, Haematologica, vol.99, pp.1410-1420, 2014. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014. ,
Extramedullary involvement in multiple myeloma, Haematologica, vol.97, pp.1618-1619, 2012. ,
FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: A systematic review and metaanalysis, Clin Nucl Med, vol.37, pp.833-837, 2012. ,
Incidence and survival outcomes of extramedullary myeloma, Blood, vol.122, p.3141, 2013. ,
Impact of next generation flow minimal residual disease monitoring in multiple myeloma: Results from the PETHEMA/ GEM2012 trial, Blood, vol.130, p.905, 2017. ,
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma, Haematologica, vol.103, pp.1047-1053, 2018. ,
State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings, European Journal of Radiology, vol.83, issue.12, pp.2203-2223, 2014. ,
Prognostic added value of PET textural features at diagnosis in symptomatic multiple myeloma, J Nucl Med, vol.58, 2017. ,
Quantitative dynamic (18)F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma, Haematologica, vol.104, pp.420-423, 2019. ,
Low expression of hexokinase-2 is associated with false-negative FDG?positron emission tomography in multiple myeloma, Blood, vol.130, issue.1, pp.30-34, 2017. ,
Hexokinase-2 Expression in 11C-Methionine?Positive, 18F-FDG?Negative Multiple Myeloma, Journal of Nuclear Medicine, vol.60, issue.3, pp.348-352, 2018. ,
Functional imaging methods for assessment of minimal residual disease in multiple myeloma: Current status and novel immunoPET based methods, Semin Hematol, vol.55, pp.22-32, 2018. ,
Assessing response of myeloma bone disease with diffusion-weighted MRI, Br J Radiol, vol.85, pp.1198-1203, 2012. ,
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: Early changes in lesional signal fat fraction predict disease response, Br J Haematol, vol.176, pp.222-233, 2017. ,
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma, Radiology, vol.271, pp.785-794, 2014. ,
About the authors and disclosure of conflicts of interest, Pharmaceutical Care in Digital Revolution, pp.xvii-xxi, 2019. ,
, Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
, Takeda Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Sanofi Travel, Accommodations, Expenses: Janssen-Cilag, Celgene, Amgen Christina Nanni Honoraria: GE Healthcare, Blue Earth Diagnostics Travel, Accommodations, Expenses: Tema Thomas Carlier Travel, Accommodations, Expenses: Siemens Healthineers Paola Tacchetti Honoraria: Celgene, Janssen-Cilag
, Accommodations, Expenses: Novartis Stephane Chauvie Stock and Other Ownership Interests: Dixit srl Speakers' Bureau: Terumo, Sirtex Medical Research Funding: Hoffmann-La Roche Andrea Gallamini Honoraria: Takeda Consulting or Advisory Role: Takeda Barbara Gamberi Honoraria: Celgene Consulting or Advisory Role: Amgen, Celgene, Janssen, Sanofi Margaret Macro Consulting or Advisory Role: Celgene, Amgen, Takeda Research Funding: Takeda (Inst)
, Laurent Garderet Consulting or Advisory Role: Amgen, Takeda, Novartis, Bristol Myers Squibb Travel, Accommodations, Expenses: Bristol Myers Squibb, Amgen Stefano Fanti Honoraria: Bayer, Sanofi, Astellas Pharma, Janssen, Sofie Travel, Accommodations, Expenses: Bayer, Blue Earth Diagnostics, Sanofi, Astellas Pharma Aurore Perrot Honoraria
, Lionel Karlin Employment: Aguettant (I) Honoraria: Amgen, Celgene, Janssen-Cilag, Takeda Consulting or Advisory Role: Amgen, Celgene, Janssen-Cilag, Takeda, GlaxoSmithKline Travel, Accommodations, Expenses: Amgen